StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
Metrics to compare | SZLSh | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSZLShPeersSector | |
---|---|---|---|---|
P/E Ratio | - | −4.9x | −0.6x | |
PEG Ratio | - | −0.02 | 0.00 | |
Price/Book | - | −0.8x | 2.6x | |
Price / LTM Sales | - | 2.7x | 3.3x | |
Upside (Analyst Target) | - | 75.3% | 39.1% | |
Fair Value Upside | Unlock | −1.6% | 5.4% | Unlock |